Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...
Add Yahoo as a preferred source to see more of our stories on Google. A magnetic resonance imaging (MRI) scan is an important tool to help doctors see what’s happening inside your body. But new, ...
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents A manganese-based MRI contrast agent could ...
Magnetic resonance imaging (MRI) has become an indispensable diagnostic modality in clinical medicine. Cluster-based magnetic resonance imaging contrast agents (MRICAs) demonstrate significant ...
Bayer BAYRY announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, for use ...
GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results